With over 0.14 million Streamline Health Solutions Inc. (STRM) shares trading Friday and a closing price of $1.64 on the day, the dollar volume was approximately $0.23 million. The shares have shown a positive half year performance of 15.67% and its price on 01/13/23 lost nearly -1.80%. Currently, there are 47.73M common shares owned by the public and among those 35.41M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for STRM have a consensus price objective of $3.00. The analysts have set the share’s price value over the next 12 months at a high of $3.00 and a low of $3.00. The average price target is 45.33% above its recent price level and an upside to the estimated low will see the stock gain 45.33% over that period. But an upside of 45.33% will see the stock hit the forecast high price target while median target price for the stock is $3.00.
Insiders at the company have transacted a total of 20 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 13 of these insider trades were purchases, accounting for 2,121,031 shares. Insider sales of the common stock occurred on 7 occasions, with total insider shares sold totaling 58,474 shares.
The top 3 mutual fund holders in Streamline Health Solutions Inc. are Vanguard Total Stock Market Index, Herald Investment Trust Plc, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.92 million shares of the company’s stock, all valued at over $1.45 million. The company bought an additional 16400.0 shares recently to bring their total holdings to about 1.60% of the shares outstanding. Vanguard Extended Market Index Fu now owns shares totaling to 1.01% of the shares outstanding.
Shares of Streamline Health Solutions Inc. (NASDAQ: STRM) opened at $1.72, up $0.05 from a prior closing price of $1.67. However, the script later moved the day high at 1.7200, down -1.80%. The company’s stock has a 5-day price change of -9.89% and 38.98% over the past three months. STRM shares are trading 3.80% year to date (YTD), with the 12-month market performance up to 17.14% higher. It has a 12-month low price of $1.04 and touched a high of $2.05 over the same period. STRM has an average intraday trading volume of 48.02K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.37%, -6.80%, and 9.40% respectively.
Institutional ownership of Streamline Health Solutions Inc. (NASDAQ: STRM) shares accounts for 29.70% of the company’s 47.73M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $95.91M and a beta (3y monthly) value of 1.17. The earnings-per-share (ttm) stands at -$0.19. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.00% over the week and 6.68% over the month.
Analysts forecast that Streamline Health Solutions Inc. (STRM) will achieve an EPS of -$0.06 for the current quarter, -$0.04 for the next quarter and -$0.17 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.06 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.1 a year ago. Earnings per share for the fiscal year are expected to decrease by -1.50%, and 29.20% over the next financial year. EPS should grow at an annualized rate of 15.00% over the next five years, compared to 12.20% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Streamline Health Solutions Inc. (STRM) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the STRM, a number of firms have released research notes about the stock. Lake Street stated their Buy rating for the stock in a research note on November 21, 2022, with the firm’s price target at $3.